Filter
1419
Text search:
intellectual
property
Featured
172
329
Language
Document type
494
318
274
155
96
40
27
6
3
3
Countries
126
24
23
22
22
18
18
18
16
12
12
12
12
11
10
10
10
10
9
9
8
8
8
8
8
8
8
8
7
7
7
7
6
5
5
5
5
5
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
270
197
143
114
72
49
37
1
Toolboxes
128
127
109
82
79
71
68
58
57
55
45
40
38
33
18
18
15
11
11
6
5
3
3
Global Action Plan on Antimicrobial Resistance
recommended
The goal of the draft global action plan is to ensure, for as long as possible, continuity of successful treatment and prevention of infectious diseases with effective and safe medicines that are quality-assured, used in a responsible way, and accessible to all who need them.
There is an urgent need for safer, simpler, more efficacious and accessible treatment regimens for all forms of TB. The development of Target Product Profiles for TB treatment regimens (referred to as Target Regimen Profiles or TRPs) seeks to guide the drug development process towards important regi
...
The purpose of this document is to provide interim guidance to laboratories and stakeholders involved in laboratory testing for Middle East respiratory syndrome coronavirus (MERS-CoV).
Shoman et al. Globalization and Health (2017) 13:1 DOI 10.1186/s12992-016-0224-2
Interim Guidance
The 2014–2015 Ebola epidemic in western Africa was the longest and most deadly Ebola epidemic in history, resulting in 28,616 cases and 11,310 deaths in Guinea, Liberia, and Sierra Leone. The Ebola virus has been known since 1976, when two separate outbreaks were identified in the Democratic Repub
...
Examination of the business behavior of Boehringer Ingelheim, Bayer and Baxter in India
Examination of the business behaviour of Boehringer Ingelheim, Bayer and Baxter in Uganda
Towards the Peoples Health Assembly Book -1
This guideline is intended to provide recommendations to applicants wishing to submit applications for the registration of medicines. It represents the Medicines Control Council’s current thinking on the safety, quality and efficacy of medicines.
Working Document, September 2017
